Containing Waxes, Higher Fatty Acids, Higher Fatty Alcohols, Or Derivatives Thereof (e.g., Chocolate) Patents (Class 424/476)
-
Patent number: 11617712Abstract: The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system.Type: GrantFiled: July 1, 2015Date of Patent: April 4, 2023Assignee: SpecGX LLCInventors: Alex Micka, Kai Feng, Tsz Chung Lai, Jonathan Gaik
-
Patent number: 10905694Abstract: The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises: (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50% or greater; and (c) at least one member selected from the group consisting of carmellose, sodium carboxy methyl starch, crospovidone, and low substituted hydroxypropylcellulose with an average particle diameter of 30 to 70 ?m, and a 90% cumulative particle diameter of 100 to 200 ?m.Type: GrantFiled: June 20, 2008Date of Patent: February 2, 2021Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Shinsuke Nakagawa, Kai Suzuki, Tadashi Mukai
-
Patent number: 10299745Abstract: A traceable device and procedure suitable for investigating gastrointestinal motility disorders by measuring transit time of the device as it is passed through the gastrointestinal tract of a patient. The device includes a core material configured to be imaged with a gamma imaging process and optionally also an x-ray imaging process, and a sealing material substantially insoluble in gastrointestinal fluids and fully encapsulating the core material.Type: GrantFiled: December 28, 2015Date of Patent: May 28, 2019Assignee: Loyola University of ChicagoInventor: Robert Hans Wagner
-
Patent number: 9827203Abstract: The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage.Type: GrantFiled: July 25, 2016Date of Patent: November 28, 2017Assignee: The Procter & Gamble CompanyInventors: Mark Edward Stella, Elissa Nicole Knights
-
Patent number: 9572781Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.Type: GrantFiled: May 3, 2010Date of Patent: February 21, 2017Assignee: Adare Pharmaceuticals, Inc.Inventors: Gopi Venkatesh, Michael Gosselin, James Clevenger, Jin-Wang Lai
-
Patent number: 9351939Abstract: The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage.Type: GrantFiled: August 14, 2013Date of Patent: May 31, 2016Assignee: The Procter & Gamble CompanyInventors: Mark Edward Stella, Elissa Nicole Knights
-
Publication number: 20150086627Abstract: Oral and parenteral dosage forms comprising halofuginone, including enteric-coated solid oral dosage forms, subcutaneous dosage forms and intravenous dosage forms, for administration to subjects in need thereof, e.g., subjects having been identified with musculoskeletal disorders, fibrotic diseases, malaria, or cancer are described herein.Type: ApplicationFiled: March 29, 2013Publication date: March 26, 2015Applicant: HALO THERAPEUTICS, LLC.Inventors: Ernest D. Bush, Diane Mcguire, Marc B. Blaustein
-
Patent number: 8900606Abstract: A method improves stability of drugs in a solid pharmaceutical formulation against oxygen and water vapor by coating the solid pharmaceutical formulation with a coating material including a high hydrogen-bonding resin and a swelling clay.Type: GrantFiled: March 12, 2013Date of Patent: December 2, 2014Assignee: Toray Industries, Inc.Inventors: Yuki Hayashi, Yuki Fujisaki, Ryoji Yoshii
-
Publication number: 20140341963Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.Type: ApplicationFiled: May 9, 2014Publication date: November 20, 2014Applicant: ActiveSignal Holding LimitedInventor: Ward Warren
-
Patent number: 8771739Abstract: The present invention provides a pharmaceutical composition of a practically insoluble drug, wherein the composition may be administered with food or without food. The composition may be in the form of a solid dispersion of the practically insoluble drug and a polymer having acidic functional groups, and the composition may in vitro form a suspension.Type: GrantFiled: June 15, 2007Date of Patent: July 8, 2014Assignee: Mayne Pharma International Pty LtdInventors: David Hayes, Angelo M. Morella
-
Patent number: 8758813Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.Type: GrantFiled: April 25, 2013Date of Patent: June 24, 2014Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander M. Klibanov
-
Publication number: 20140154318Abstract: There is provided a lotion tablet for the delivery of oxygen having an outer layer or “crust” coating an interior, that liberates oxygen upon rupture of the crust. The oxygen may be generated in the interior upon rupture of the crust or may be pre-formed or dissolved in the interior prior to coating the interior with the crust. The tablet would be easy to carry in airplanes, for example, making it readily available to the customer. Furthermore, the consumer may peel/tear open as many tablets as they desire, according to their needs/preference.Type: ApplicationFiled: December 3, 2012Publication date: June 5, 2014Applicant: KIMBERLY-CLARK WORLDWIDE, INC.Inventor: Shruti Aryal
-
Publication number: 20140112988Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.Type: ApplicationFiled: December 19, 2013Publication date: April 24, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
-
Patent number: 8685444Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.Type: GrantFiled: April 23, 2010Date of Patent: April 1, 2014Assignee: Alpharma Pharmaceuticals LLCInventor: Garth Boehm
-
Patent number: 8642083Abstract: Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.Type: GrantFiled: October 30, 2007Date of Patent: February 4, 2014Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Patent number: 8580305Abstract: The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine, has practically unproblematic hardness, and disintegrate rapidly in the oral cavity. This tablet is produced by tabletting cores coated with a pharmaceutical disintegrating agent, wherein the core is a granule containing a water-soluble medicament or containing a medicament and a sugar.Type: GrantFiled: January 20, 2004Date of Patent: November 12, 2013Inventors: Tomoharu Suga, Tomio Nakano
-
Publication number: 20130251794Abstract: The present invention relates to a method for “hot melt coating” of pharmaceutical active ingredients characterized by organoleptic or physicochemical properties that it is desirable to mask. The invention also relates to the resulting medicinal active ingredients with masked organoleptic or physicochemical properties and the compositions comprising same.Type: ApplicationFiled: October 22, 2012Publication date: September 26, 2013Applicant: SANOFIInventors: Axelle Lesot, Damia Leydet, Arnaud Moussel
-
Patent number: 8449909Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: GrantFiled: June 25, 2010Date of Patent: May 28, 2013Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
-
Publication number: 20130122092Abstract: The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders.Type: ApplicationFiled: July 22, 2011Publication date: May 16, 2013Applicant: AMBROS PHARMA S.R.L.Inventor: Bojidar Mihaylov Stankov
-
Patent number: 8372812Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.Type: GrantFiled: February 24, 2010Date of Patent: February 12, 2013Assignee: Aker Biomarine ASAInventors: Snorre Tilseth, Nils Hoem
-
Patent number: 8282956Abstract: A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate.Type: GrantFiled: June 12, 2007Date of Patent: October 9, 2012Assignee: Nippon Shinyaku Co. Ltd.Inventors: Hironobu Kato, Hirokazu Sakamoto
-
Publication number: 20120189693Abstract: Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm.Type: ApplicationFiled: June 25, 2010Publication date: July 26, 2012Applicant: Elite Laboratories, Inc.Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
-
Publication number: 20120082721Abstract: The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form.Type: ApplicationFiled: May 28, 2010Publication date: April 5, 2012Applicant: H E X A L AktiengesellschaftInventors: Christian Buessing, Marco Marchesan, Andreas Krekeler
-
Patent number: 8147874Abstract: Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/or are coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of ?5, and/or (ii) a melting range of ?60° C., and/or (iii) a solidification range ? of less than 35° C., and/or (iv) a density of ?0.80 g cm?3.Type: GrantFiled: June 12, 2009Date of Patent: April 3, 2012Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Irwin Jacobs
-
Patent number: 8105691Abstract: By coating the surface of a powder comprising a silicone resin and/or an organic powder with a specific hydrophilizing agent, such powder is hydrophilized. Such coated (treated) powder has extremely great dispersibility (ease of dispersion) and very good dispersion stability (long-term dispersion stability with lapse of time) in aqueous dispersion media, particularly under acidic and alkaline conditions, specifically at pH 3 through 13. Using the surface-treated powder, additionally, a dispersion with good dispersibility (ease of dispersion) and great dispersion stability, preferably for cosmetics can be provided. The use of the surface-treated powder, or the use of the dispersion can provide further a cosmetic excellent in dispersibility and dispersion stability and further in re-dispersibility and dispersion stability with lapse of time and smooth feeling as compared to the related art when selecting aqueous cosmetic as an agent form.Type: GrantFiled: June 21, 2006Date of Patent: January 31, 2012Assignee: Miyoshi Kasei, Inc.Inventors: Yasushi Takeuchi, Shinya Kuwazuru, Masaakira Horino
-
Publication number: 20110280942Abstract: A film coating composition comprising a cellulosic polymer, an opacifying agent, and a fatty acid is disclosed herein. Also disclosed is a film coating composition comprising a cellulosic polymer, an opacifying agent, a plasticizing agent, and a polyol. The disclosed film coating compositions may be mixed with a solvent to produce a film coating suspension. The film coating suspension can be applied to a substrate, such as a nutritional supplement, pharmaceutical, tablet, capsule, softgel, granule, particle, food confectionary form, agricultural seed, and the like to form a film coating on the substrate. Methods of coating a substrate with the film coating suspensions are also provided.Type: ApplicationFiled: May 11, 2011Publication date: November 17, 2011Inventors: Beverly A. Schad, Brian K. Cheng
-
Patent number: 7988998Abstract: A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.Type: GrantFiled: April 22, 2005Date of Patent: August 2, 2011Assignees: Labopharm Inc., Labopharm Europe Limited, Labopharm (Barbados) LimitedInventors: Vincent Lenaerts, Patricia Laure Ouadji-Nijki, Jonathan Bacon, Rachid Ouzérourou, Sonia Gervais, Miloud Rahmouni, Damon Smith
-
Publication number: 20110008412Abstract: A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or more substantially water resistant materials.Type: ApplicationFiled: September 22, 2010Publication date: January 13, 2011Applicant: CIPLA LIMITEDInventors: Amar LULLA, Geena MALHOTRA
-
Patent number: 7803402Abstract: A pharmaceutical extended-release oral drug delivery system comprising as active ingredient Cefixime Trihydrate in combination with a hydrophilic matrix system, and optionally containing additional pharmaceutically acceptable constituents, wherein at least 20% up to but not more than 40% of Cefixime Trihydrate is released from said matrix within 1 hour from oral administration and the remainder of the pharmaceutical agent is released at a sustained rate.Type: GrantFiled: June 6, 2003Date of Patent: September 28, 2010Inventors: Sanjeev Khandelwal, Pratibha Omray
-
Patent number: 7785650Abstract: Water soluble, gelatin-free dip coatings for pharmaceutical solid dosage forms such as tablets comprising HPMC and xanthan gum, carrageenan, and mixtures thereof, or HPMC and castor oil or maltodextrin.Type: GrantFiled: June 27, 2007Date of Patent: August 31, 2010Assignee: McNeil-PPC, Inc.Inventors: Cynthia Gulian, Walter G. Gowan, Jr., Kishor B. Parekh, Joseph M. Morris, Thomas J. Markley, Dennis C. Wieand, Gerard P. McNally, Christopher Szymczak
-
Publication number: 20100203134Abstract: The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids.Type: ApplicationFiled: April 23, 2010Publication date: August 12, 2010Applicant: EthypharmInventors: Philippe Chenevier, Dominique Marechal
-
Publication number: 20100159003Abstract: The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C.Type: ApplicationFiled: June 12, 2008Publication date: June 24, 2010Applicant: ratiopharm GmbHInventors: Yogesh S. Deshpande, Sandra Brueck, Julia Schulze Nahrup, Birgit Schnitter, Ganesh Gat, Javed Hussain
-
Publication number: 20100074951Abstract: Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.Type: ApplicationFiled: October 30, 2007Publication date: March 25, 2010Applicant: HANALL PHARMACEUTICAL COMPANY, LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jae Woon Son
-
Publication number: 20100074949Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.Type: ApplicationFiled: August 13, 2009Publication date: March 25, 2010Inventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D.J. Grootenhuis, Martyn Botfield, Alfredo Grossi
-
Publication number: 20100068274Abstract: An object of the present invention is to provide a dry coating method which can coat a tablet in a simple manner and with high efficiency, and therefore can produce a tablet having good appearance and hardly causing breaking/cracking. The present invention provides a process for producing a tablet coated with a coating agent comprising a meltable substance, comprising the steps of: heating a plain tablet to a temperature equal to or higher than a melting point of the meltable substance; and contacting the plain tablet with the coating agent to coat the plain tablet.Type: ApplicationFiled: April 25, 2008Publication date: March 18, 2010Applicant: EISAI R & D MANAGEMENT CO., LTD.Inventors: Nao Ono, Norio Shimogaki
-
Publication number: 20090274757Abstract: Polish compositions for coating pharmaceutical solid dosage forms such as tablets are disclosed. The polish composition comprises water, coating agent, and a film forming agent. Polished pharmaceutical solid dosage forms such as tablets comprising a polished exterior surface are also disclosed. Processes of polishing pharmaceutical solid dosage forms such as tablets are disclosed.Type: ApplicationFiled: April 30, 2009Publication date: November 5, 2009Applicant: WYETHInventor: John C. CLARK
-
Publication number: 20090252794Abstract: The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge.Type: ApplicationFiled: August 9, 2007Publication date: October 8, 2009Inventors: Tetsuya Suzuki, Koji Tokutomi, Tatsuo Nomura, Chika Ohno, Tetsuro Yoshinari
-
Patent number: 7537784Abstract: A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) a moisture barrier surrounding said control releasing coat, wherein the modified-release tablet is bioequivalent to Wellbutrin® or Zyban®/Wellbutrin®SR tablets.Type: GrantFiled: June 13, 2006Date of Patent: May 26, 2009Assignee: Biovail Laboratories International SRLInventors: Werner Oberegger, Okponanabofa Eradiri, Fang Zhou, Paul Maes
-
Patent number: 7510729Abstract: The invention relates to the combination of polyvinyl acetate and water-insoluble, acid-insoluble, or alkali-insoluble polymers used for producing film coatings for forms of administration in which agents are released in a controlled manner, and methods for the production thereof. The controlled-release properties can be specifically adjusted by means of said combinations, resulting in films having excellent mechanical stability and storage stability. In particular, agents are released independent of the pH by means of the inventive forms of administration.Type: GrantFiled: March 11, 2003Date of Patent: March 31, 2009Assignee: BASF AktiengesellschaftInventors: Karl Kolter, Roland Bodmeier, Andriy Dashevskiy
-
Publication number: 20080050432Abstract: The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are expressed at intervals. The formulation of the present invention comprises statin-based lipid-lowering agent and dihydropyridine-based calcium channel blocker that affects cytochrome P450 enzyme as active ingredients, and is such constituted that the release rates of the aforementioned ingredients are different, thus preventing antagonism and side effects, while maintaining the synergistic effect, which leads to the convenience in medication.Type: ApplicationFiled: April 5, 2007Publication date: February 28, 2008Inventors: Sung Soo Jun, Young Gwan Jo, Ja-Seong Koo, Jin Wook Kim, Ju-Bin Yim
-
Publication number: 20080031946Abstract: The invention relates to low-dose tablets obtained by directly compressing microgranules essentially constituted of a neutral support covered by a polymeric layer containing at least one pharmaceutically acceptable polymer and permitting the modified release of active substances in an aqueous medium, to which an active layer containing at least one active substance is applied. The inventive tablets advantageously exhibit a matrix effect similar to that obtained with conventional matrix tablets that depends on the nature of the polymer(s) used for the constitution of the polymeric layer. This matrix effect makes it possible to modify the release profile of the transported active substance based on the type of the polymer used. These tablets are particularly suited for realizing low-dose tablets. The invention also relates to a method for producing these tablets and to the use thereof, particularly for administering active substances in low to very low doses.Type: ApplicationFiled: November 10, 2004Publication date: February 7, 2008Applicant: ETHYPHARMInventors: Pierre Tchoreloff, Bernard Leclerc, Guillaume Benoist, Laurent Bertocchi
-
Publication number: 20080014271Abstract: The present invention relates to pharmaceutical compositions comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation.Type: ApplicationFiled: March 2, 2007Publication date: January 17, 2008Applicant: UCB, S.A.Inventors: Caroline Goffin, Michael Boonen
-
Patent number: 7318936Abstract: This invention relates to compositions and methods for preventing oxidation of beneficial agents.Type: GrantFiled: November 12, 2004Date of Patent: January 15, 2008Assignee: Alza CorporationInventors: Zhongli Ding, Lothar Walter Kleiner
-
Patent number: 7235258Abstract: Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.Type: GrantFiled: October 19, 2000Date of Patent: June 26, 2007Assignee: NPS Pharmaceuticals, Inc.Inventors: David S. Wells, Lian G. Rajewski, Thomas B. Marriott, James D. Pipkin, John L. Haslam
-
Patent number: 7235253Abstract: A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.Type: GrantFiled: November 28, 2001Date of Patent: June 26, 2007Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Yoshinobu Hanyu, Mariko Okada, Chihiro Shindo, Satoshi Nishimuro, Tetsuo Yokoyama, Masato Horie
-
Patent number: 7220430Abstract: The present invention is to provide a sustained release preparation comprising a drug-containing core substance and a multilayered coating layer covering the core substance, wherein all adjacent layers in the multilayered coating layer contain mutually different hydrophobic organic compound-water-soluble polymer mixtures; and, a method of producing a sustained release preparation, having a multilayered coating layer in which adjacent layers contain different hydrophobic organic compound-water-soluble polymer mixtures, which comprises spray-coating a solution containing a hydrophobic organic compound-water-soluble polymer mixture onto a drug-containing core substance, continuing to spray-coat a solution containing a different hydrophobic organic compound-water-soluble polymer mixture onto the resulting coating layer, and repeating this step.Type: GrantFiled: January 26, 2001Date of Patent: May 22, 2007Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Takashi Ishibashi, Kengo Ikegami, Keigo Nagao, Hiroyuki Yoshino, Masakazu Mizobe
-
Patent number: 7147870Abstract: The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations.Type: GrantFiled: August 18, 2003Date of Patent: December 12, 2006Assignee: Osmotica Corp.Inventors: Joaquina Faour, Marcelo A. Ricci
-
Patent number: 6994873Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.Type: GrantFiled: February 4, 2002Date of Patent: February 7, 2006Assignee: Valpharma S.A.Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
-
Patent number: 6939560Abstract: The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.Type: GrantFiled: December 15, 2000Date of Patent: September 6, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Robert W. Shen, Gerald A. Walter
-
Patent number: RE39069Abstract: The present invention provides a simple and improved multi-layered osmotic device (1) that is capable of delivering a first active agent in an outer lamina (2) to one environment of use and a second active agent in the core (5) to another environment of use. Particular embodiments of the invention provide osmotic devices in which the first and second active agents are similar or dissimilar. An erodible polymer coat (3) between an internal semipermeable membrane (4) and a second active agent-containing external coat (2) comprises poly(vinylpyrrolidone)-(vinyl acetate) copolymer. This particular erodible polymer results in an improved multi-layered osmotic device possessing advantages over related devices known in the art. The active agent in the core (5) is delivered through a pore (6) containing an erodible plug (7). The osmotic device (1) can be coated by a final finish coat (8).Type: GrantFiled: December 3, 2001Date of Patent: April 18, 2006Assignee: Osmotica Corp.Inventors: Joaquina Faour, Jorge E. Mayorga